Faruqi & Faruqi Urges Tvardi Therapeutics Investors Amid Class Action Deadline Approaching
Class Action Alert: Tvardi Therapeutics Investors
Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities litigation, is encouraging shareholders of Tvardi Therapeutics, Inc. (NASDAQ: TVRD) to reach out regarding a pending class action lawsuit. A critical deadline approaches for potential lead plaintiffs, set for November 3, 2025. This notification comes in the wake of alarming news after a significant drop in Tvardi's stock value following disappointing clinical trial results.
Background on Tvardi Therapeutics
Tvardi Therapeutics, a company focused on pioneering therapies for various diseases, particularly idiopathic pulmonary fibrosis, experienced a drastic decline in its stock price by over 80% on October 13, 2025. This sharp fall was triggered when the company released preliminary data from its Phase 2 REVERT clinical trial assessing the safety and efficacy of TTI-101. Unfortunately, these initial findings indicated that the study did not meet its outlined objectives, raising questions about the future of the company and its products.
What Happened During the Trial?
The REVERT clinical trial aimed to evaluate the effects of TTI-101 in patients suffering from idiopathic pulmonary fibrosis, focusing on safety metrics and lung function indicators, particularly Forced Vital Capacity (FVC). The results showed similar baseline characteristics across treatment groups, except for the placebo group, which exhibited a lower percent predicted FVC. This disappointing news has left investors and stakeholders concerned about the company’s viability and future prospects.
Investor Call to Action
In the aftermath of these developments, Faruqi & Faruqi, led by Senior Partner James 'Josh' Wilson, is reaching out to shareholders who may have suffered substantial financial losses due to these events. The law firm has a commendable track record of successfully recovering millions for investors since its inception in 1995. They are now offering their legal expertise to assist those affected by the recent stock plunge and navigate their options moving forward.
Investors are urged to act quickly, as the deadline to become a lead plaintiff in this class action is approaching. For individuals who have experienced significant losses in Tvardi's stock or options, direct communication is recommended. Interested parties can contact Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for further discussions about their legal rights and potential claims.
Conclusion
As this situation continues to evolve, it highlights the risks associated with investments in biotechnology firms, especially those reliant on clinical trial outcomes. Investors should stay informed and consider their next steps carefully. Faruqi & Faruqi remains committed to advocating for the rights of all investors affected by this downturn. To keep updated on the Tvardi investigation, visit www.faruqilaw.com/TVRD.
This alert serves as a critical reminder of the importance of thorough due diligence and the need for legal representation in times of financial uncertainty. Investors are strongly recommended to seek advice and representation that can help them safeguard their investments during this time of turmoil for Tvardi Therapeutics.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.